Cancer Family
Malignant Breast Neoplasm
CI-CAN-00000227Explore in graph →
Top-level2,628 active trials43 approved drugs310 evidence items
- NCIt
- C9335
- ICD-10
- C50
- DOID
- 1612
- Other
- 2 more codes
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000227Explore in graph →
Variants & evidence
464 evidence items mapped to this entity or its descendants, grouped by molecular profile, then therapy. 50 items per page.
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| PIK3CA E545K4 | ||||||||
| Trastuzumab | HER2-Positive Breast CarcinomaALIAS | Predictive | D | Supports Resistance | 2 | accepted | EID1453PI3K mutant E545K was overexpressed in the trastuzumab sensitive HER2 BT474 breast cancer cell line, and significant resistance to trastuzumab was induced in comparison to control cells. PMID 18829560 · Serra et al., 2008 · Open in CIViC | civic |
| 〃 | HER2-Positive Breast CarcinomaALIAS | Predictive | D | Supports Resistance | 2 | accepted | EID8547As part of a pre-clinical experiment, the efficacy of trastuzumab was evaluated against various HER2 positive cell lines. MCF7-neo/HER2 cell line harboring PIK3CA E545K was associated with resistance … (full text at CIViC) PMID 26920887 · Baselga et al., 2016 · Open in CIViC | civic |
| Dactolisib + Lapatinib + TrastuzumabCombination | HER2-Positive Breast CarcinomaALIAS | Predictive | D | Supports Sensitivity Response | 2 | submitted | EID8181In a preclinical study, efficacy of trastuzumab, lapatinib, and NVP-BEZ235 (dactolisib) combination therapy was evaluated in vitro against HER2 amplified breast cancer cell line BT474 with retrovirall… (full text at CIViC) PMID 19010894 · Eichhorn et al., 2008 · Open in CIViC | civic |
| Trastuzumab Emtansine | HER2-Positive Breast CarcinomaALIAS | Predictive | D | Does Not Support Resistance | 3 | accepted | EID2036As part of a pre-clinical experiment, the efficacy of ado-trastuzumab emtansine (T-DM1) was compared to that of trastuzumab against various HER2 positive cell lines. MCF7-neo/HER2 cell line harboring … (full text at CIViC) PMID 26920887 · Baselga et al., 2016 · Open in CIViC | civic |
| PIK3CA E545A + PIK3CA E545D + PIK3CA E545G + PIK3CA E545K1 | ||||||||
| Alpelisib + FulvestrantCombination | Malignant Breast Neoplasm | Predictive | A | Supports Sensitivity Response | 4 | accepted | EID7468In a phase 3 trial, 572 patients with hormone receptor positive, HER2 receptor negative advanced breast cancer who previously received endocrine therapy were allocated to alpelisib plus fulvestrant or… (full text at CIViC) PMID 31091374 · André et al., 2019 · Open in CIViC | civic |
| PIK3CA E545A + PIK3CA E545D + PIK3CA E545G + PIK3CA E545K + PIK3CA E545L + PIK3CA E545Q + PIK3CA E545R + PIK3CA E545V1 | ||||||||
| Fulvestrant + Inavolisib + PalbociclibCombination | Malignant Breast Neoplasm | Predictive | A | Supports Sensitivity Response | 3 | accepted | EID12534The phase III INAVO120 trial (NCT04191499) in 325 patients with endocrine-resistant, PIK3CA-mutated HR⁺/HER2⁻ locally advanced or metastatic breast cancer evaluated inavolisib plus palbociclib and ful… (full text at CIViC) PMID 40845250 · Wedam et al., 2025 · Open in CIViC | civic |
| PIK3CA E545V1 | ||||||||
| Trastuzumab | Malignant Breast Neoplasm | Predictive | C | Supports Resistance | — | submitted | EID2072In HER2-positive metastic breast cancer patients treated with trastuzumab-based therapy, the presence of a PIK3CA mutation was associated with an increased risk of progression (HR:2.50, 95% CI:1.35-4.… (full text at CIViC) PMID 21594665 · Razis et al., 2011 · Open in CIViC | civic |
| PIK3CA Exon 10 Mutation1 | ||||||||
| (prognostic) | Malignant Breast Neoplasm | Prognostic | B | Supports Poor Outcome | 4 | accepted | EID6199An Italian study of 163 malignant breast tumors assessed the association between PIK3CA mutations and clinical outcome. Of the 163 tumors sequenced, 118 had wild-type (wt) PIK3CA, 24 had exon 9 (helic… (full text at CIViC) PMID 17947469 · Barbareschi et al., 2007 · Open in CIViC | civic |
| PIK3CA Exon 21 Mutation1 | ||||||||
| (prognostic) | Malignant Breast Neoplasm | Prognostic | B | Supports Better Outcome | 4 | accepted | EID6198An Italian study of 163 malignant breast tumors assessed the association between PIK3CA mutations and clinical outcome. Of the 163 tumors sequenced, 118 had wild-type (wt) PIK3CA, 24 had exon 9 (helic… (full text at CIViC) PMID 17947469 · Barbareschi et al., 2007 · Open in CIViC | civic |
| PIK3CA G1049A + PIK3CA G1049C + PIK3CA G1049D + PIK3CA G1049R + PIK3CA G1049S + PIK3CA G106A + PIK3CA G106D + PIK3CA G106R + PIK3CA G106S + PIK3CA G106V + PIK3CA G118D1 | ||||||||
| Fulvestrant + Inavolisib + PalbociclibCombination | Malignant Breast Neoplasm | Predictive | A | Supports Sensitivity Response | 3 | accepted | EID12537The phase III INAVO120 trial (NCT04191499) in 325 patients with endocrine-resistant, PIK3CA-mutated HR⁺/HER2⁻ locally advanced or metastatic breast cancer evaluated inavolisib plus palbociclib and ful… (full text at CIViC) PMID 40845250 · Wedam et al., 2025 · Open in CIViC | civic |
| PIK3CA H1047L3 | ||||||||
| PI-103 | Malignant Breast Neoplasm | Predictive | D | Supports Sensitivity Response | 1 | accepted | EID8009As part of a preclinical study, the efficacy of PI-103 was evaluated for several cell lines of breast cancer. Sensitivity and resistance was categorized as less than and more than an IC50 of 1umol/L, … (full text at CIViC) PMID 20453058 · O'Brien et al., 2010 · Open in CIViC | civic |
| PI3Ka/Di | Malignant Breast Neoplasm | Predictive | D | Supports Sensitivity Response | 1 | accepted | EID8019As part of a preclinical study, the efficacy of PI3KA/Di—a selective inhibitor for the α and δ subunits of class I PI3K—was evaluated for several cell lines of breast cancer. Sensitivity and resistanc… (full text at CIViC) PMID 20453058 · O'Brien et al., 2010 · Open in CIViC | civic |
| Pictilisib | Malignant Breast Neoplasm | Predictive | D | Supports Sensitivity Response | ||||
| PIK3CA H1047L or H1047R1 | ||||||||
| Imatinib | Malignant Breast Neoplasm | Predictive | E | Does Not Support Resistance | 1 | rejected | civic | |
| PIK3CA H1047R18 | ||||||||
| (prognostic) | Malignant Breast Neoplasm | Prognostic | B | Supports Better Outcome | 2 | accepted | EID2097Prognostic significance of PIK3CA mutations was evaluated in a retrospective study of 590 patients with surgically resected invasive breast cancer. Patients whose tumors harbored PIK3CA H1047R (n=88, … (full text at CIViC) PMID 19671852 · Kalinsky et al., 2009 · Open in CIViC | civic |
| 〃 | Malignant Breast Neoplasm | Prognostic | B | Supports Better Outcome | 2 | accepted | EID2100In Japanese invasive breast cancer patients, PIK3CA mutation was associated with improved relapse-free survival (p < .05). PMID 17202311 · Maruyama et al., 2007 · Open in CIViC | civic |
| Capivasertib + LapatinibCombination | HER2-Positive Breast CarcinomaALIAS | Predictive | D | |||||
| PIK3CA H1047L + PIK3CA H1047R1 | ||||||||
| (prognostic) | Breast Tubular Carcinoma | Prognostic | B | Supports Poor Outcome | 1 | accepted | EID3047In a retrospective analysis of 32 Western Chinese female patients with invasive ductal breast cancer, PIK3CA H1047L (n=1) or H1047R (n=8) was associated with worse survival and increased incidence of … (full text at CIViC) PMID 28269754 · Cheng et al., 2017 · Open in CIViC | civic |
| PIK3CA H1047L + PIK3CA H1047R + PIK3CA H1047Y1 | ||||||||
| Alpelisib + FulvestrantCombination | Malignant Breast Neoplasm | Predictive | A | Supports Sensitivity Response | 5 | accepted | EID7318In a phase 3 trial, patients with hormone receptor positive, HER2 receptor negative breast were allocated to alpelisib plus fulvestrant or placebo plus fulvestrant. Patients were enrolled into two coh… (full text at CIViC) PMID 31091374 · André et al., 2019 · Open in CIViC | civic |
| PIK3CA H1047D + PIK3CA H1047I + PIK3CA H1047L + PIK3CA H1047N + PIK3CA H1047P + PIK3CA H1047Q + PIK3CA H1047R + PIK3CA H1047T + PIK3CA H1047Y1 | ||||||||
| Fulvestrant + Inavolisib + PalbociclibCombination | Malignant Breast Neoplasm | Predictive | A | Supports Sensitivity Response | 3 | accepted | EID12533The phase III INAVO120 trial (NCT04191499) in 325 patients with endocrine-resistant, PIK3CA-mutated HR⁺/HER2⁻ locally advanced or metastatic breast cancer evaluated inavolisib plus palbociclib and ful… (full text at CIViC) PMID 40845250 · Wedam et al., 2025 · Open in CIViC | civic |
| PIK3CA I391M2 | ||||||||
| Trastuzumab | HER2-Positive Breast CarcinomaALIAS | Predictive | D | Does Not Support Resistance | 2 | accepted | EID8663As part of a pre-clinical experiment, the efficacy of trastuzumab was evaluated against various HER2 positive cell lines using cell viability assays. ZR-75-30 cell line expressing PIK3CA I391M was ass… (full text at CIViC) PMID 26920887 · Baselga et al., 2016 · Open in CIViC | civic |
| Trastuzumab Emtansine | HER2-Positive Breast CarcinomaALIAS | Predictive | D | Does Not Support Resistance | 3 | accepted | EID2867As part of a pre-clinical experiment, the efficacy of ado-trastuzumab emtansine (T-DM1) was evaluated against various HER2 positive cell lines. ZR-75-30 cell line expressing PIK3CA I391M was associate… (full text at CIViC) PMID 26920887 · Baselga et al., 2016 · Open in CIViC | civic |
| PIK3CA K111N7 | ||||||||
| Dactolisib + Lapatinib + TrastuzumabSubstitutes | HER2-Positive Breast CarcinomaALIAS | Predictive | D | Does Not Support Resistance | 2 | accepted | EID8183The BT-474 HER2 positive human breast cancer cell line, which is heterozygous for the PIK3CA K111N mutation, demonstrated strongly reduced colony formation when treated with lapatinib, trastuzumab or … (full text at CIViC) PMID 19010894 · Eichhorn et al., 2008 · Open in CIViC | civic |
| PI-103 | HER2-Positive Breast CarcinomaALIAS | Predictive | D | Supports Sensitivity Response | 1 | accepted | EID8011As part of a preclinical study, the efficacy of PI-103 was evaluated for several cell lines of breast cancer. Sensitivity and resistance was categorized as less than and more than an IC50 of 1umol/L, … (full text at CIViC) PMID 20453058 · O'Brien et al., 2010 · Open in CIViC | civic |
| PIK3CA K111N + PTEN UnderexpressionPIK3CAPTEN6 | ||||||||
| Dactolisib | HER2-Positive Breast CarcinomaALIAS | Predictive | D | Supports Resistance | 2 | accepted | EID8276In a preclinical study, efficacy of dactolisib monotherapy was evaluated in vitro against HER2 amplified human breast cancer cell line BT474 (heterozygous for PIK3CA K111N) with shRNA-induced PTEN exp… (full text at CIViC) PMID 19010894 · Eichhorn et al., 2008 · Open in CIViC | civic |
| Dactolisib + TrastuzumabCombination | HER2-Positive Breast CarcinomaALIAS | Predictive | D | Supports Sensitivity Response | 2 | submitted | EID8283In a preclinical study, efficacy of NVP-BEZ235 (dactolisib) and trastuzumab combination therapy was evaluated in vitro against HER2 amplified breast cancer cell line BT474 with shRNA-induced PTEN expr… (full text at CIViC) PMID 19010894 · Eichhorn et al., 2008 · Open in CIViC | |
Data updated 19 hours agoSource updated unknownsource: civic (CC0)
Evidence levels, directions and ratings are those assigned by CIViC curators. "Submitted" items have not completed curation review. This is not treatment guidance.
| 3 |
| accepted |
EID2089This preclinical study tested the efficacy on several breast cancer cell lines of GDC-0941 (pictilisib), a selective inhibitor of all four isoforms of class I PI3-kinases at a range of IC50 values. Se… (full text at CIViC) PMID 20453058 · O'Brien et al., 2010 · Open in CIViC |
| civic |
| 3 |
| accepted |
EID1506The HER2 breast cancer cell line KPL4 with PIK3CA H1047R shows sub-optimal responses to trastuzumab and lapatinib, and was used to establish mouse xenografts. Treatment of mice with monotherapy of AZD… (full text at CIViC) PMID 22294718 · Davies et al., 2012 · Open in CIViC |
| civic |
| Capivasertib + TrastuzumabCombination | HER2-Positive Breast CarcinomaALIAS | Predictive | D | Supports Sensitivity Response | 3 | accepted | EID1505Tumor xenografts in mice were established with the KPL4 HER2 positive breast cancer cell line with PIK3CA H1047R mutation. KPL4 has suboptimal responses to trastuzumab and lapatinib. Xengraft treatmen… (full text at CIViC) PMID 22294718 · Davies et al., 2012 · Open in CIViC | civic |
| Dactolisib | HER2-Positive Breast CarcinomaALIAS | Predictive | D | Does Not Support Resistance | 4 | accepted | EID6206This preclinical study tested the sensitivity of HER2-positive breast cancer cell line BT-474 (heterozygous for PIK3CA K111N) retrovirally transduced with PIK3CA H1047R to NVP-BEZ235 (dactolisib; a du… (full text at CIViC) PMID 19010894 · Eichhorn et al., 2008 · Open in CIViC | civic |
| Dactolisib + TrastuzumabCombination | HER2-Positive Breast CarcinomaALIAS | Predictive | D | Supports Sensitivity Response | 2 | submitted | EID8182In a preclinical study, efficacy of trastuzumab and NVP-BEZ235 (dactolisib) combination therapy was evaluated in vitro against HER2 amplified breast cancer cell line BT474 with retrovirally induced PI… (full text at CIViC) PMID 19010894 · Eichhorn et al., 2008 · Open in CIViC | civic |
| Everolimus + FulvestrantCombination | HER2-Positive Breast CarcinomaALIAS | Predictive | C | Supports Sensitivity Response | 2 | accepted | EID1623Case report of a 44-year-old patient with recurrent HER2-positive breast cancer. The primary tumor was HR positive; however, the metastatic tumor was HR negative. The patient was resistant to classica… (full text at CIViC) PMID 27445490 · Sun et al., 2016 · Open in CIViC | civic |
| Izorlisib | Malignant Breast Neoplasm | Predictive | D | Supports Sensitivity Response | 4 | accepted | EID314Breast cancer cell lines with H1047R mutation showed increased sensitivity to CH5132799 than cells with wild-type PIK3CA gene. PMID 21558396 · Tanaka et al., 2011 · Open in CIViC | civic |
| Lapatinib | HER2-Positive Breast CarcinomaALIAS | Predictive | D | Supports Resistance | 3 | accepted | EID6202This preclinical study tested, in vitro, the resistance to lapatinib (an anti-HER2 drug) of HER2-positive breast cancer cell lines (BT474 and SKBR3) retrovirally transduced with H1047R. The study foun… (full text at CIViC) PMID 19010894 · Eichhorn et al., 2008 · Open in CIViC | civic |
| Dactolisib + LapatinibCombination | HER2-Positive Breast CarcinomaALIAS | Predictive | D | Does Not Support Resistance | 3 | submitted | EID6205This preclinical study tested the sensitivity to lapatinib and NVP-BEZ235 (dactolisib; a dual PI3K/mTOR inhibitor) of a HER2-positive breast cancer cell line (BT474) retrovirally transduced with PIK3C… (full text at CIViC) PMID 19010894 · Eichhorn et al., 2008 · Open in CIViC | civic |
| Lapatinib + TrastuzumabCombination | HER2-Positive Breast CarcinomaALIAS | Predictive | D | Supports Resistance | 4 | accepted | EID6204In a preclinical study, efficacy of lapatinib and trastuzumab was evaluated in vitro against HER2 amplified breast cancer cell line BT474 (heterozygous for PIK3CA K111N) retrovirally transduced with P… (full text at CIViC) PMID 19010894 · Eichhorn et al., 2008 · Open in CIViC | civic |
| PI-103 | Malignant Breast Neoplasm | Predictive | D | Supports Sensitivity Response | 1 | submitted | EID8010As part of a preclinical study, the efficacy of PI-103 was evaluated for several cell lines of breast cancer. Sensitivity and resistance was categorized as less than and more than an IC50 of 1umol/L, … (full text at CIViC) PMID 20453058 · O'Brien et al., 2010 · Open in CIViC | civic |
| Pictilisib | HER2-Positive Breast CarcinomaALIAS | Predictive | D | Supports Sensitivity Response | 4 | accepted | EID2096This preclinical study tested the efficacy on several breast cancer cell lines of GDC-0941 (pictilisib), a selective inhibitor of all four isoforms of class I PI3-kinases at a range of IC50 values. Se… (full text at CIViC) PMID 20453058 · O'Brien et al., 2010 · Open in CIViC | civic |
| 〃 | Malignant Breast Neoplasm | Predictive | D | Supports Sensitivity Response | 2 | accepted | EID2102This preclinical study tested the efficacy of GDC-0941, a selective inhibitor of class I PI3K, on several cell lines of breast cancer. Sensitivity and resistance was categorized as less than and more … (full text at CIViC) PMID 20453058 · O'Brien et al., 2010 · Open in CIViC | civic |
| Trastuzumab | Malignant Breast Neoplasm | Predictive | B | Supports Resistance | — | submitted | EID2101In unilateral breast cancer patients, PIK3CA mutation was associated with improved local recurrence-free survival. PMID 17575221 · Pérez-Tenorio et al., 2007 · Open in CIViC | civic |
| 〃 | HER2-Positive Breast CarcinomaALIAS | Predictive | D | Supports Resistance | 3 | accepted | EID6203This preclinical study tested the effect of trastuzumab (an anti-HER2 drug) on HER2-positive breast cancer cell lines (BT474 and SKBR3) retrovirally transduced with H1047R. The study found that the H1… (full text at CIViC) PMID 19010894 · Eichhorn et al., 2008 · Open in CIViC | civic |
| 〃 | HER2-Positive Breast CarcinomaALIAS | Predictive | D | Supports Resistance | 2 | accepted | EID8548As part of a pre-clinical experiment, the efficacy of trastuzumab was evaluated against various HER2 positive cell lines. CC1954 and KPL-4 cell lines expressing PIK3CA H1047R were associated with resi… (full text at CIViC) PMID 26920887 · Baselga et al., 2016 · Open in CIViC | civic |
| Trastuzumab Emtansine | HER2-Positive Breast CarcinomaALIAS | Predictive | D | Does Not Support Resistance | 3 | accepted | EID2103As part of a pre-clinical experiment, the efficacy of ado-trastuzumab emtansine (T-DM1) was compared to that of trastuzumab against various HER2 positive cell lines. HCC1954 and KPL-4 cell lines expre… (full text at CIViC) PMID 26920887 · Baselga et al., 2016 · Open in CIViC | civic |
| HER2-Positive Breast CarcinomaALIAS |
| Predictive |
| D |
| Supports Sensitivity Response |
| 1 |
| accepted |
EID8020As part of a preclinical study, the efficacy of PI3KA/Di—a selective inhibitor for the α and δ subunits of class I PI3K—was evaluated for several cell lines of breast cancer. Sensitivity and resistanc… (full text at CIViC) PMID 20453058 · O'Brien et al., 2010 · Open in CIViC |
| civic |
| Pictilisib | HER2-Positive Breast CarcinomaALIAS | Predictive | D | Supports Sensitivity Response | 4 | accepted | EID2085This preclinical study tested the efficacy on several breast cancer cell lines of GDC-0941 (pictilisib), a selective inhibitor of all four isoforms of class I PI3-kinases at a range of IC50 values. Se… (full text at CIViC) PMID 20453058 · O'Brien et al., 2010 · Open in CIViC | civic |
| Trastuzumab | HER2-Positive Breast CarcinomaALIAS | Predictive | D | Supports Resistance | 3 | rejected | EID8550As part of a pre-clinical experiment, the efficacy of trastuzumab was compared to that of ado-trastuzumab emtansine (T-DM1) against various HER2 positive cell lines. BT-474 cell line expressing PIK3CA… (full text at CIViC) PMID 26920887 · Baselga et al., 2016 · Open in CIViC | civic |
| 〃 | HER2-Positive Breast CarcinomaALIAS | Predictive | D | Does Not Support Resistance | 2 | accepted | EID8662As part of a pre-clinical experiment, the efficacy of trastuzumab was evaluated against various HER2 positive cell lines in cell viability assays. BT-474 cell line expressing PIK3CA K111N was associat… (full text at CIViC) PMID 26920887 · Baselga et al., 2016 · Open in CIViC | civic |
| Trastuzumab Emtansine | HER2-Positive Breast CarcinomaALIAS | Predictive | D | Does Not Support Resistance | 3 | accepted | EID2866As part of a pre-clinical experiment, the efficacy of ado-trastuzumab emtansine (T-DM1) was evaluated against various HER2 positive cell lines. BT-474 cell line expressing PIK3CA K111N was associated … (full text at CIViC) PMID 26920887 · Baselga et al., 2016 · Open in CIViC | civic |
| civic |
| Lapatinib | HER2-Positive Breast CarcinomaALIAS | Predictive | D | Supports Resistance | 4 | accepted | EID8275In a preclinical study, efficacy of trastuzumab monotherapy was evaluated in vitro against HER2 amplified human breast cancer cell line BT474 (heterozygous for PIK3CA K111N) with shRNA-induced PTEN ex… (full text at CIViC) PMID 19010894 · Eichhorn et al., 2008 · Open in CIViC | civic |
| Dactolisib + LapatinibCombination | HER2-Positive Breast CarcinomaALIAS | Predictive | D | Does Not Support Resistance | 2 | accepted | EID8278In a preclinical study, efficacy of NVP-BEZ235 (dactolisib; a dual PI3K/mTOR inhibitor) and lapatinib combination therapy was evaluated in vitro against HER2 amplified breast cancer cell line BT474 (h… (full text at CIViC) PMID 19010894 · Eichhorn et al., 2008 · Open in CIViC | civic |
| Lapatinib + TrastuzumabCombination | HER2-Positive Breast CarcinomaALIAS | Predictive | D | Supports Sensitivity Response | 2 | submitted | EID8277In a preclinical study, efficacy of lapatinib and trastuzumab combination therapy was evaluated in vitro against HER2 amplified breast cancer cell line BT474 with shRNA-induced PTEN expression loss. A… (full text at CIViC) PMID 19010894 · Eichhorn et al., 2008 · Open in CIViC | civic |
| Trastuzumab | HER2-Positive Breast CarcinomaALIAS | Predictive | D | Supports Resistance | 2 | accepted | EID8274In a preclinical study, efficacy of trastuzumab monotherapy was evaluated in vitro against HER2 amplified human breast cancer cell line BT474 (heterozygous for PIK3CA K111N) with shRNA-induced PTEN ex… (full text at CIViC) PMID 19010894 · Eichhorn et al., 2008 · Open in CIViC | civic |